• The firm had applied for the authorisation of the vaccine ZyCoV-D on July 1, based on an efficacy rate of 66.6% in a late-stage trial of more than 28,000 volunteers nationwide.
Ifemu ibifake isicelo sokugunyazwa kweZyCoV-D ngoJulayi 1, ngokuya ngesilinganiso sokusebenza kwamaphesenti angama-66.6 esivivinyweni esiseduze kakhulu samavolontiya angaphezu kwama-28,000 ezweni lonke.